- Trial phase
- Approved in China (NMPA); Phase III ongoing for cGVHD
- Time to market
- Already marketed in China. Timeline for US/EU regulatory filings is not yet disclosed; Sanofi is still in early-stage global development.
- Why 3/10
- No hard dated catalyst (PDUFA, pivotal readout) is scheduled in the next ~12 months. The drug is already approved and commercializing in China, and Sanofi is a large diversified pharma for which this is a small pipeline asset. The Phase III cGVHD trial is still recruiting with no disclosed readout date.
Watch for Sanofi's progress advancing rovadicitinib into US/EU clinical trials and any Phase III cGVHD data readouts, which would be the next meaningful catalysts. The drug is already generating commercial revenue in China, but for Sanofi's stock, this is a minor contributor relative to Dupixent and other core franchises.
Price Chart
Executive Summary
Anxu (rovadicitinib) is a first-in-class oral JAK/ROCK dual inhibitor approved in China since February 2026 for myelofibrosis. Sanofi licensed global rights in March 2026 for $135M upfront and up to $1.53B total. The drug launched in China in Q2 2026 with Sanofi reporting initial sales in Q3 2026. Sanofi's core interest is in chronic graft-versus-host disease (cGVHD), where a Phase III trial is ongoing in China. No US or EU regulatory filing has occurred yet. For a company the size of Sanofi, this is a small pipeline addition with no imminent binary catalyst.
How It Works
Anxu is a pill that blocks two cellular pathways (JAK-STAT and ROCK) involved in inflammation and fibrosis. By inhibiting both pathways simultaneously, it aims to reduce abnormal cell growth and inflammatory signaling in bone marrow cancers like myelofibrosis and in immune-driven conditions like chronic graft-versus-host disease.
Trial Status
Approved in China for first-line myelofibrosis (February 2026). A Phase III trial for moderate-to-severe chronic graft-versus-host disease (cGVHD) in third-line and beyond is recruiting in China (NCT06682169). Phase Ib/IIa data for cGVHD published in Blood showed a 59.1% overall response rate and corticosteroid dose reduction in 88.6% of patients.
The Two-Sided Case
Upcoming Catalysts
- Phase III cGVHD trial data readout (NCT06682169, recruiting as of August 2026, no estimated completion date published)
- Potential US IND filing and early-phase trial initiation by Sanofi
- Quarterly China sales trajectory updates from Sanofi earnings
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report